CLNN Stock Overview
A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Clene Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.17 |
| 52 Week High | US$12.00 |
| 52 Week Low | US$3.82 |
| Beta | 0.42 |
| 11 Month Change | -22.78% |
| 3 Month Change | -22.78% |
| 1 Year Change | -54.67% |
| 33 Year Change | -95.59% |
| 5 Year Change | -98.00% |
| Change since IPO | -97.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| CLNN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.9% | -3.7% | 0.3% |
| 1Y | -54.7% | 15.2% | 31.1% |
Return vs Industry: CLNN underperformed the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: CLNN underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| CLNN volatility | |
|---|---|
| CLNN Average Weekly Movement | 12.9% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CLNN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CLNN's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 84 | Rob Etherington | clene.com |
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain’s energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson’s Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution.
Clene Inc. Fundamentals Summary
| CLNN fundamental statistics | |
|---|---|
| Market cap | US$32.00m |
| Earnings (TTM) | -US$36.02m |
| Revenue (TTM) | US$421.00k |
79.0x
P/S Ratio-0.9x
P/E RatioIs CLNN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLNN income statement (TTM) | |
|---|---|
| Revenue | US$421.00k |
| Cost of Revenue | US$90.00k |
| Gross Profit | US$331.00k |
| Other Expenses | US$36.36m |
| Earnings | -US$36.02m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.51 |
| Gross Margin | 78.62% |
| Net Profit Margin | -8,556.77% |
| Debt/Equity Ratio | -431.9% |
How did CLNN perform over the long term?
See historical performance and comparison